First SGLT2 Inhibitor Approved for Kids With Type 2 Diabetes
(MedPage Today) -- Two empagliflozin-containing treatments were FDA approved for pediatric type 2 diabetes, the agency announced on Tuesday.
Once-daily empagliflozin (Jardiance) and empagliflozin/metformin hydrochloride (Synjardy) are now indicated...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Children | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Fortamet | International Medicine & Public Health | Jardiance | Metformin | Pediatrics | SGLT2 Inhibitors